FMA
CLVS

FNY Managed Accounts’s Clovis Oncology, Inc. CLVS Stock Holding History

FNY Managed Accounts’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-500
Closed -$18K – 307
2016
Q3 		$18K Buy
+500
New +$10.7K 0.02% 285

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FNY Managed Accounts's CLVS Position: Q4 2016 in Review

FNY Managed Accounts sold out of Clovis Oncology, Inc. (CLVS) in Q4 2016, closing a stake of 500 shares — an estimated $18K sold.

FNY Managed Accounts first reported a position in CLVS in Q3 2016 and held it in 1 quarter. The position peaked at $18K in Q3 2016. 167 funds tracked by Wall St. Rank hold CLVS as of Q4 2016.

  • FNY Managed Accounts reported no remaining Clovis Oncology, Inc. position as of Q4 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 500 Clovis Oncology, Inc. shares in Q4 2016, an estimated $18K.
  • FNY Managed Accounts first reported a position in Clovis Oncology, Inc. in Q3 2016 and held it in 1 quarter.
  • FNY Managed Accounts's Clovis Oncology, Inc. position peaked at $18K in Q3 2016.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2016.

Based on FNY Managed Accounts's 13F filing for Q4 2016, filed 8 Feb 2017.